🚀
Enjoy a 7-Day Free Trial Thru May 03, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ)
News
PhaseBio Pharmaceuticals Inc
OTCPK
:PHASQ (USA)
$ 0.00
0 (0%)
10:09 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 5.00K
Enterprise V:
$ -2.43M
Volume:
-
Avg Vol (2M):
-
Warning! GuruFocus detected issues with PHASQ.
Try a 7-Day Free Trial
to check it out.
Volume:
-
Market Cap $:
5.00K
PE Ratio:
At Loss
Avg Vol (2M):
-
Enterprise Value $:
-2.43M
PB Ratio:
0
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) Stock News, Headlines & Updates
PhaseBio Pharmaceuticals Inc Stock News from GuruFocus
Total 60
1
2
Jul 19, 2022
Top 5 2nd Quarter Trades of MAI Capital Management
GuruFocus Research
•
1:00pm
Jun 30, 2021
PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15
Business Wire
•
4:00pm
Jun 17, 2021
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
Business Wire
•
8:00am
May 20, 2021
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference
Business Wire
•
4:00pm
May 17, 2021
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session
Business Wire
•
4:01pm
May 13, 2021
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
Business Wire
•
4:00pm
Mar 11, 2021
PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab
Business Wire
•
10:59am
Feb 27, 2021
PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire
•
7:00pm
Feb 25, 2021
PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021
Business Wire
•
7:02pm
Jan 28, 2021
PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor
Business Wire
•
11:01am
PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress
Business Wire
•
7:01pm
Nov 13, 2020
PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results
Business Wire
•
7:01pm
Nov 12, 2020
PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
Business Wire
•
7:01pm
Oct 23, 2020
PhaseBio Provides Pemziviptadil (PB1046) Program Update
Business Wire
•
11:01am
Oct 06, 2020
PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor
Business Wire
•
11:00am
Sep 10, 2020
PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Business Wire
•
7:00pm
Aug 04, 2020
PhaseBio to Present at the William Blair Biotech Focus Conference 2020
Business Wire
•
7:01pm
Jul 17, 2020
PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients
Business Wire
•
7:00pm
May 28, 2020
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
Business Wire
•
7:00pm
May 13, 2020
PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights
Business Wire
•
7:01pm
Feb 27, 2020
PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference
Marketwired
•
7:00pm
Feb 14, 2020
PhaseBio Appoints Alex C. Sapir to Board of Directors
Marketwired
•
7:01pm
Feb 11, 2020
PhaseBio Announces European Regulatory Update for PB2452
Marketwired
•
11:00am
Feb 05, 2020
PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress
Marketwired
•
7:00pm
Jan 14, 2020
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension
Marketwired
•
7:00pm
Jan 10, 2020
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
Marketwired
•
11:00am
Nov 15, 2019
PhaseBio to Present at Stifel 2019 Healthcare Conference
Marketwired
•
7:00am
Nov 14, 2019
PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress
Marketwired
•
11:01am
Nov 08, 2019
PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019
Marketwired
•
7:00pm
Oct 25, 2019
PhaseBio Expands Executive Management Team
Marketwired
•
7:01pm
Oct 15, 2019
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
Marketwired
•
11:01am
Sep 25, 2019
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
Marketwired
•
7:00pm
Sep 03, 2019
Pharmacodynamics Evaluation of PhaseBio's Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019
Marketwired
•
11:00am
Aug 26, 2019
PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019
Marketwired
•
11:00am
Aug 14, 2019
PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452
Marketwired
•
7:01am
Aug 07, 2019
PhaseBio To Report Second Quarter 2019 Financial Results and Recent Corporate Progress on August 13, 2019
Marketwired
•
7:02pm
Jul 01, 2019
PhaseBio Added to Russell 2000® and 3000® Indexes
Marketwired
•
11:01am
Jun 18, 2019
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating PhaseBio Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PRNewswire
•
11:04am
PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects
Marketwired
•
7:00pm
May 10, 2019
PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress
Marketwired
•
7:01pm
Total 60
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news